(Reuters) – Biogen Inc's quarterly adjusted profit blew past Wall Street estimates on higher sales of its multiple sclerosis drugs, and the company said Chief Executive George Scangos would leave in the coming months. Shares of the company, whose board also authorized a $5 billion share repurchase program, rose about 5 percent to $276 in premarket trading on Thursday. Sales of the company's portfolio of multiple sclerosis drugs largely came ahead of consensus estimates compiled by Evercore ISI.
Read more here:
U.S. drugmaker Biogen’s profit beats Street; CEO to leave